A key opinion leader discusses the evolving treatment landscape for radioiodine refractory differentiated thyroid carcinoma, with special consideration of the phase 3 SELECT trial.

EP. 1: Phase 3 SELECT Trial Overview

Targeted Oncology

July 13th 2020

Watch

EP. 2: SELECT Trial: Toxicity, Duration of Response, and Dose Reduction

Targeted Oncology

July 13th 2020

Watch

$What is Radioiodine-Refractory DTC?$

EP. 3: What is Radioiodine-Refractory DTC?

Targeted Oncology

July 13th 2020

Watch

$Radioiodine-Refractory DTC: NCCN Guidelines$

EP. 4: Radioiodine-Refractory DTC: NCCN Guidelines

Targeted Oncology

July 13th 2020

Watch

EP. 5: Multikinase Inhibitor Overall Survival Advantage

Watch

Do Not Sell My Information

Privacy

Terms & Conditions

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777